What BPC-157 is
BPC-157 is discussed as a gastric peptide fragment with proposed effects on repair signaling, vascular response, and inflammatory pathways.
BPC-157 is grouped under Fitness + Recovery on PeptideFactCheck because it is one of the most searched recovery peptides online, especially around tendon, gut, and soft-tissue claims.
The useful starting point is to separate the molecule itself from the internet story around it. The public story is simple: BPC-157 is framed as a repair peptide that helps damaged tissue calm down and rebuild faster.
Why people keep looking it up
People usually look it up for faster recovery, tendon or ligament support, gut irritation, and soft-tissue repair.
The biology people point to is repair signaling: blood-vessel response, inflammation control, and tissue remodeling in injury models.
BPC-157 tends to stay in the conversation because it touches a familiar public theme: tissue repair, angiogenesis signal, and inflammation. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
The strongest support is still preclinical. The popular human recovery claims are much louder than the published human evidence.
Published human evidence is limited for the broad recovery claims that drive its internet popularity.
The strongest public evidence is preclinical, including animal and mechanistic work around injury models and tissue response.
Why this page carries the current tier: High search demand with mostly preclinical support and unresolved regulatory context.
The current seed trail for BPC-157 is pulling from 1 literature source, 1 trials source, 1 databases source, and 1 safety source.
Safety, limits, and regulatory context
Unknowns include product quality, immune response, impurities, route-specific risk, and whether model findings translate to durable human benefit.
No FDA-approved BPC-157 drug product is listed in this V1 source trail. FDA bulk-substance policy has changed over time, so compounding status should be verified directly against FDA sources before publication updates.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for BPC-157. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for BPC-157 is CID 9941957. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 9941957
- Formula
- C62H98N16O22
- Molecular weight
- 1419.5
- InChIKey
- HEEWEZGQMLZMFE-RKGINYAYSA-N
Matched synonyms include 137525-51-0, Bpc-157, Bpc 157, Bepecin, Bpc 15, L-Valine, glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-, pl-10, 8ED8NXK95P.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for BPC-157 returns 2 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for BPC-157 returns 214 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.